このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Nanologica 将来の成長

Future 基準チェック /26

Nanologicaは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	46.4%
収益成長率	83.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	08 Jul 2024

今後の成長に関する最新情報

Recent updates

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Feb 23

業績と収益の成長予測

OM:NICA - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	232	N/A	N/A	N/A	1
12/31/2025	139	N/A	N/A	N/A	1
12/31/2024	49	N/A	N/A	N/A	1
6/30/2024	8	-76	-54	-46	N/A
3/31/2024	8	-80	-61	-49	N/A
12/31/2023	5	-75	-57	-36	N/A
9/30/2023	6	-53	-59	-42	N/A
6/30/2023	7	-53	-57	-36	N/A
3/31/2023	7	-51	-51	-34	N/A
12/31/2022	6	-55	-54	-45	N/A
9/30/2022	5	-56	-55	-49	N/A
6/30/2022	6	-57	-60	-56	N/A
3/31/2022	9	-53	-61	-58	N/A
12/31/2021	15	-45	-52	-46	N/A
9/30/2021	21	-35	-48	-44	N/A
6/30/2021	21	-28	-40	-34	N/A
3/31/2021	21	-23	-45	-39	N/A
12/31/2020	18	-22	-47	-43	N/A
9/30/2020	14	-24	-47	-33	N/A
6/30/2020	14	-24	-39	-27	N/A
3/31/2020	14	-23	-48	-16	N/A
12/31/2019	12	-21	-20	-10	N/A
9/30/2019	12	-18	-11	-9	N/A
6/30/2019	11	-18	-17	-14	N/A
3/31/2019	8	-19	-14	-11	N/A
12/31/2018	6	-21	-15	-12	N/A
9/30/2018	7	-18	-26	-24	N/A
6/30/2018	6	-18	-28	-26	N/A
3/31/2018	5	-19	N/A	-21	N/A
12/31/2017	5	-20	N/A	-23	N/A
9/30/2017	3	-22	N/A	-17	N/A
6/30/2017	4	-24	N/A	-18	N/A
3/31/2017	4	-24	N/A	-24	N/A
12/31/2016	4	-22	N/A	-23	N/A
9/30/2016	5	-23	N/A	-25	N/A
6/30/2016	5	-21	N/A	-19	N/A
3/31/2016	7	-18	N/A	-17	N/A
12/31/2015	9	-14	N/A	-14	N/A
9/30/2015	8	-14	N/A	N/A	N/A
6/30/2015	9	-15	N/A	N/A	N/A
3/31/2015	7	-14	N/A	N/A	N/A
12/31/2014	7	-15	N/A	N/A	N/A
12/31/2013	5	-10	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NICAの予測収益成長が貯蓄率 ( 1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: NICAの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: NICAの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: NICAの収益 ( 74.3% ) Swedish市場 ( 1.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: NICAの収益 ( 74.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NICAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Nanologica 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 25% to kr12.00

No longer forecast to breakeven

Price target decreased to kr16.50

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

New major risk - Market cap size

Nanologica AB (Publ) Elects Alexandra Blomberg Montgomery as New Member of the Board of Directors

New major risk - Share price stability

New major risk - Financial position

Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.41 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: kr0.46 loss per share (vs kr0.34 loss in 1Q 2023)

Nanologica AB (publ) Announces Chief Operating Officer Changes

New minor risk - Shareholder dilution

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Price target decreased by 25% to kr12.00

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Nanologica AB (publ) to Report Q2, 2024 Results on Jul 05, 2024

Insufficient new directors

New minor risk - Share price stability

Nanologica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 54.2 million.

New major risk - Financial position

Third quarter 2023 earnings released: kr0.32 loss per share (vs kr0.39 loss in 3Q 2022)

Nanologica AB (publ), Annual General Meeting, May 16, 2024

Nanologica AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

New minor risk - Financial position

Second quarter 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in 2Q 2022)

Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?

Chief Scientific Officer, Gary Pitcairn Will Leave Nanologica AB (publ)

First quarter 2023 earnings released: kr0.34 loss per share (vs kr0.56 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

No longer forecast to breakeven

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr16.50

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Nanologica (NGM:NICA) A Risky Investment?

No longer forecast to breakeven

Third quarter 2021 earnings released: kr0.45 loss per share (vs kr0.32 loss in 3Q 2020)

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

First quarter 2021 earnings released: kr0.28 loss per share (vs kr0.40 loss in 1Q 2020)

Full year 2020 earnings released: kr0.80 loss per share (vs kr1.18 loss in FY 2019)

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Nanologica Recruits PK Dutta as SVP Sales and Senior Advisor for Chromatography

New 90-day high: kr15.30

Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery Platforms

New 90-day high: kr13.80

Nanologica AB Engages Scientific Advisors Within Inhalation

Nanologica AB (Publ) Delivers Test Material from Large Scale Production

Nanologica AB (publ) to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high: kr15.05

First half earnings released

New 90-day high - kr14.00

Nanologica AB (publ) to Report Q2, 2020 Results on Aug 21, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘